Hattori Sou, Ojima Eiji, Okauchi Shinichiro, Sasatani Yuika, Shiozawa Toshihiro, Satoh Hiroaki, Hizawa Nobuyuki
Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Division of Cardiology, Mito Medical Center, University of Tsukuba, Mito, Japan.
Cancer Diagn Progn. 2022 Nov 3;2(6):711-715. doi: 10.21873/cdp.10165. eCollection 2022 Nov-Dec.
BACKGROUND/AIM: Anaplastic lymphoma kinase (ALK) rearrangements define a distinct group of patients with non-small-cell lung cancer (NSCLC), mainly represented by never-smoking young individuals. However, we also encounter elderly patients with ALK-rearranged NSCLC over the age of 80 years. We report herein three cases of these patients that we have experienced.
Three patients with ALK-rearranged NSCLC aged 80 years or older received therapy with the ALK-tyrosine kinase, alectinib. Of them, one was male and two had a history of smoking. Comorbidities, especially heart diseases, were prominent. Long-term survival was achieved with alectinib treatment in two patients.
ALK-rearranged mutations should be evaluated even in octogenarians with NSCLC, regardless of sex and smoking history. Even if they have comorbid diseases, long-term control might be achieved with alectinib therapy in cooperation with physicians other than chest physicians and medical oncologists.
背景/目的：间变性淋巴瘤激酶（ALK）重排定义了一组独特的非小细胞肺癌（NSCLC）患者，主要以从不吸烟的年轻个体为代表。然而，我们也遇到了80岁以上的ALK重排NSCLC老年患者。我们在此报告我们所经历的三例此类患者。
三名80岁及以上的ALK重排NSCLC患者接受了ALK酪氨酸激酶阿来替尼治疗。其中一名为男性，两名有吸烟史。合并症，尤其是心脏病，较为突出。两名患者通过阿来替尼治疗实现了长期生存。
即使是患有NSCLC的八旬老人，无论性别和吸烟史如何，都应评估ALK重排突变。即使他们患有合并症，与胸科医生和肿瘤内科医生以外的医生合作，通过阿来替尼治疗也可能实现长期控制。
